Stocksigma LogoStocksigma Logo

US FDA Approves Sun Pharma's ILUMYA for Active Psoriatic Arthritis

On 30th Oct'26, Sun Pharma announced that the US FDA approved its supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) to treat

US FDA Approves Sun Pharma's ILUMYA for Active Psoriatic Arthritis

Sun Pharmaceutical Industries Ltd 路 Press Release 路 30 Oct 2026, 1:35 pm

US FDA Approves Sun Pharma's ILUMYA for Active Psoriatic Arthritis On 30th Oct'26, Sun Pharma announced that the US FDA approved its supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) to treat adults with active psoriatic arthritis (PsA). Supported by Phase 3 INSPIRE-1 and INSPIRE-2 trials, this approval expands ILUMYA's label beyond moderate-to-severe plaque psoriasis, targeting an estimated addressable population of ~2.4m Americans living with PsA. The IL-23 inhibitor is administered exclusively by healthcare providers, strengthening Sun Pharma's high-growth global innovative medicines portfolio, which currently accounts for ~20% of company sales.

Original exchange filing (PDF)

More announcements from Sun Pharmaceutical Industries Ltd

All Sun Pharmaceutical Industries Ltd announcements